Neuromuscular Blockers In ARDS

Early neuromuscular blockade for acute respiratory distress syndrome (ARDS) remains a debated clinical strategy due to conflicting results from the 2010 ACURASYS trial and the recent ROSE study. While ACURASYS demonstrated a mortality benefit with heavy sedation and neuromuscular agents, the ROSE trial found no such advantage, likely due to differences in sedation protocols, PEEP levels, and the utilization of prone positioning. Reverse triggering—a phenomenon where ventilator-delivered breaths induce patient respiratory efforts—emerges as a plausible mechanism for these discrepancies, suggesting that heavy sedation may inadvertently increase lung injury. Expert Arthur Slutsky emphasizes shifting from routine paralysis to a physiological approach, prioritizing prone positioning and identifying patients with high respiratory drive or significant dyssynchrony. These findings underscore the necessity of evidence-based, individualized care in intensive care settings while cautioning against the over-reliance on small-scale positive trials.